DSD. Sadykova

D. Sadykova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


D. Sadykova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experience with combined immunomodulatory and antiviral therapy for chronic endometritis with a viral component in women with reproductive failure: A prospective study

    by Tatiana P. Zefirova, Gulrukhsor K. Tolibova, Dina A. Sadykova, Georgy S. Nikitin

    Background. Chronic endometritis (CE) is a multifaceted pathology, with ongoing revisions in the understanding of its etiology, pathogenesis, and treatment modalities. The lack of standardized, universally accepted algorithms for diagnosing and managing CE results in inconsistent diagnoses and patient care. While the role of bacterial infection is well established, it is recognized that antibacterial therapy does not yield favorable outcomes in every case. Increasing evidence suggests that various microorganisms, alongside bacteria, contribute significantly to this condition. Notably, CE associated with viral factors in the endometrium presents with various cytopathic effects, often resulting in persistent morphofunctional disorders of the uterine mucosa. Viral agents such as human papillomavirus (HPV) and herpes simplex viruses types 1 and 2 (HSV-1, HSV-2) can persist in the endometrium. In women with CE and reproductive failure (RF), the prevalence of HPV and HSV endometrial infections may reach up to 93.3%. Combination therapy, integrating antiviral medications with immunomodulatory agents, is emerging as a promising strategy to enhance interferon production and activate cellular immunity. Aim. To conduct a comparative analysis of the clinical efficacy of two therapeutic regimens: monotherapy with valacyclovir vs. a combination therapy with 1 mg of alloferon (Allokin-alpha®) and valacyclovir in patients with RF, associated with viral contamination of the endometrium and CE. Materials and methods. The prospective study involved 30 women diagnosed with CE and RF. A comprehensive morphological study of endometrial biopsy specimen was performed within days 19–23 of the menstrual cycle, along with an immunohistochemical assessment to identify viral antigens and evaluate p16ink4a protein expression. Following clinical and laboratory examinations that confirmed the diagnosis of viral CE, participants were randomized into two groups: Group 1 (n = 15) received valacyclovir monotherapy (500 mg twice daily for 10 days from Day 1 of the menstrual cycle for two months); Group 2 (n = 15) received combination therapy with valacyclovir (according to a similar regimen for two months) and alloferon (Allokin-alpha®) administered subcutaneously at 1 mg in 1 ml of 0.9% NaCl solution every other day from Day 1 of the menstrual cycle, totaling nine injections in the first month of treatment. Follow-up endometrial biopsies were collected for control examinations four months post-treatment, within the luteal phase of the cycle (Days 19–23). Results. At the preliminary stage, all patients were diagnosed with chronic virus-associated endometritis. Mono-infection was detected in 33.3% of cases, whereas combined viral infections, primarily HPV in association with HSV-1 and/or HSV-2, accounted for 66.7% of observations. A comparative analysis showed that the combination regimen was statistically superior to monotherapy in terms of treatment efficacy. Complete eradication of viruses from the endometrium was observed in 60% of patients receiving combination therapy, compared with 20% in the monotherapy group. Furthermore, no mixed viral associations were detected following combination treatment (p = 0.025). Morphological evaluations confirmed a marked regression of chronic inflammation in the combination therapy group, with mild lymphohistiocytic infiltration noted in 86.7% of patients. An important effect of combination therapy was a substantial reduction in p16ink4a expression in the endometrium (p = 0.011), thereby suggesting a restoration of cell cycle regulation. Follow-up assessments over 12 months post-treatment revealed significant differences in reproductive outcomes during this period (p = 0.026). Conclusion. The combination therapy involving alloferon and valacyclovir demonstrated superior efficacy when compared to valacyclovir monotherapy, as evidenced by pronounced improvements in the histological findings in the endometrium and a decrease in p16ink4a protein expression. This combined therapeutic approach presents a promising approach for enhancing reproductive outcomes in patients with viral CE.

  • Open Access

    Vaginal infections in pregnant women: diagnosis, new paradigms of therapy. A prospective study

    by Natalia M. Podzolkova, Tatiana P. Zefirova, Larisa G. Sozaeva, Dina A. Sadykova

    Background. Vaginal infection complicates the course of pregnancy and adversely affects perinatal outcomes for the mother and fetus. With the global increase in microorganism resistance to antimicrobial drugs, the treatment of vaginitis in pregnant women is not always effective, leading to recurrent pathology. Therefore, seeking new therapeutic solutions is a pressing task. Aim. To evaluate the effectiveness of a new form of benzyl-dimethyl [3-(myristoylamino) propyl] ammonium chloride monohydrate (Miramistin® suppositories) in the treatment of vaginitis in pregnant women. Materials and methods. A prospective study included 60 pregnant women with a confirmed diagnosis of nonspecific vaginitis. All patients received therapy with Miramistin® suppositories vaginally once a day for 7 days. Clinical dynamics and microbiological characteristics of the vaginal biotope were assessed. Results. Disappearance or significant reduction of clinical symptoms was noted in 96.7% of pregnant women within two days from the start of treatment. The duration of the relapse-free period was more than 4 weeks. No adverse drug reactions were observed. There was high satisfaction with the treatment results among both physicians and patients. Conclusion. Treating vaginitis in pregnant women using the new form of benzyl-dimethyl [3-(myristoylamino) propyl] ammonium chloride monohydrate (Miramistin® suppositories) is an effective method for controlling vaginal infection.


  • Open Access

    Pheno-genotypic features of family hypercholesterolemia in children

    by D. Sadykova, E. Slastnikova, L. Galimova, C. Khaliullina, K. Salakhova

  • Assessment of the global, segmental left ventricle stain in children with family hypercholesterolemia

    by L. Galimova, D. Sadykova, E. Slastnikova, C. Khaliullina, K. Salakhova

  • Open Access

    HYPERTRIGLYCERIDEMIA AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASES

    by Luiza M. Nurieva, Kazan City Clinical Hospital No. 7, Zulfiya F. Kim, Albert S. Galyvich, Dinara I. Sadykova, Kazan State Medical University


  • Membrane serotonin transporter as a Biomarker of Pulmonary arterial hypertension in children with Congenital Heart Defect

    by F. Mindubayeva, Y. Niyazova, R. Nigmatullina, D. Sadykova, L. Akhmaltdinova, Y. Salikhova, I. Kadyrova, M Akhmetova, D. Sabirova

    18 young children (aged from 1 month old to 2 years old) with congenital heart disease were observed. During observation they were divided into 2 groups. Group I-8 children with CHD, not complicated by PAH. Group II 11 children with CHD, complicated by PAH. The content of serotonin and its transporter in platelets, the amount of serotonin in serum were determined. Serotonin content was determined by enzyme-linked immunosorbent assay. The study was performed using the Serotonin ELISA diagnostic kit, IBL Hamburg on the Evolis automated robotic station (BioRad). To determine the Sodium-Dependent serotonin transporter (SLC6A4) there was used the method of quantitative sandwich ELISA of Cusabio production. The main initiator of the development of PAH is development of endothelial dysfunction of the pulmonary vessels. Since the cause of this dysfunction is associated with functional disorders of the serotonergic system, our task was to determine the content of SERT and serotonin in platelets in the studied groups. We suggest that the serotonin transporter (SERT), which is responsible for the proliferation of the pulmonary artery smooth-muscle cells (PASMC), can be used as a biomarker for predicting and diagnosing PAH in children with CHD. The need for early biomarkers in the diagnosis of PAH in children is claimed by scientists from many countries of the world [1, 2]. The results of our studies showed a significant increase in the concentration of SERT in platelets in group II, compared with group I more than several times. The serotonin content in platelets in children of group II tended to decrease as compared with group I. Perhaps, an excessive increase in transporters in platelets is sufficient in itself for the induction of PASMC hyperplasia and the subsequent development of PAH. It is necessary to continue research in this direction, which will help to reveal and understand the molecular mechanisms by which SERT regulates the proliferation of PASMC and the role of serotonin and its transporter in the development of PAH in children.